The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer

ConclusionsThe continuous use of bevacizumab beyond progressive disease improves post-progression survival suggesting its important role in first-line and recurrence treatment for ovarian cancer.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research